Maximize Returns with AI-Powered OPT Insights

OPT Forecast

Bullish Case: FDA approval of OPT-302 could catalyze a price surge by unlocking significant market potential in age-related vision disorders, especially with supportive sentiment momentum.

Bearish Case: Failure in clinical trials or financial instability could further depress stock prices, exacerbated by competitive pressures and high operational costs.

Potential Outcomes:

1. FDA approval for OPT-302: 30% probability, +100% price increase.
2. Clinical trial failure: 50% probability, -50% price drop.
3. Acquisition by a larger company: 20% probability, +30% rise.

March 12, 2025

Opthea Limited Forecast

OPT Opthea Limited

Price Forecast
Future Uncertainty

4 Day Price Forecast + Historical Performance. Video Tutorial: Trade Smarter With Helium's AI Forecasts

9 Day Price Forecast + Historical Performance. Video Tutorial: Trade Smarter With Helium's AI Forecasts

20 Day Price Forecast + Historical Performance. Video Tutorial: Trade Smarter With Helium's AI Forecasts

36 Day Price Forecast + Historical Performance. Video Tutorial: Trade Smarter With Helium's AI Forecasts

49 Day Price Forecast + Historical Performance. Video Tutorial: Trade Smarter With Helium's AI Forecasts

See Longer Forecasts

Correlated Assets

Assets that tend to move strongly with OPT

BYRN Byrna (0.75)

MCD McDonald's (0.72)

LYV Live Nation Entertainment (0.72)

BBW Build A Bear Workshop (0.71)

DOX Amdocs (0.71)

Uncorrelated Assets

Assets with little price relationship to OPT

TRIP TripAdvisor (0.0)

PRU Prudential Financial (0.0)

CVS CVS Health (0.01)

HCA HCA Healthcare (-0.01)

MFA MFA Financial (0.02)

Anticorrelated Assets

Assets that tend to move strongly against OPT

CLW Clearwater Paper (-0.56)

WFRD Weatherford International plc - New (-0.57)

ST Sensata (-0.59)

AMC AMC Entertainment (-0.65)

BIIB Biogen (-0.67)

Become a more profitable investor with AI optimized trading strategies

Market Forecasts

Bullish / Bearish

Digital Assets / Most Accurate

Trading Strategies

Long Volatility

Short Volatility

Balanced News

Balanced News / Sources

Tech / Memes / Politics

About

About / Pricing / Forum

Contact Helium Trades

2024 © Helium Trades
Privacy Policy & Disclosure

* Disclaimer: Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions, you should consult a financial expert before engaging in any transaction.